XFOR

Zacks Small Cap Research – XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… – Go Health Pro

by

By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Licensing Agreement with Norgine Includes €28.5 Million Upfront Payment On January 13, 2025, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced an exclusive licensing and supply agreement with Norgine, a European specialty pharmaceutical company that generates greater than €500 million in annual revenues, that covers Europe, … Read more

Zacks Small Cap Analysis – XFOR: First Business Gross sales of XOLREMDI… – Go Well being Professional

by
Zacks Small Cap Analysis – XFOR: First Business Gross sales of XOLREMDI… – Go Well being Professional

By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Monetary Replace On August 8, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced monetary outcomes for the second quarter of 2024. The corporate recorded the primary revenues for XOLREMDI following its industrial launch in April 2024. Income within the second quarter of 2024 totaled $0.6 … Read more

x